Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Amarin Corp ADR (AMRN)

Amarin Corp ADR (AMRN)
8.76 x 1 9.40 x 10
Post-market by (Cboe BZX)
9.11 -0.25 (-2.67%) 04/17/25 [NASDAQ]
8.76 x 1 9.40 x 10
Post-market 9.11 unch (unch) 16:00 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.84
Day High
9.34
Open 9.01
Previous Close 9.36 9.36
Volume 115,100 115,100
Avg Vol 103,590 103,590
Stochastic %K 73.86% 73.86%
Weighted Alpha -43.65 -43.65
5-Day Change +0.08 (+0.89%) +0.08 (+0.89%)
52-Week Range 7.08 - 20.60 7.08 - 20.60
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,065
  • Shares Outstanding, K 20,534
  • Annual Sales, $ 228,610 K
  • Annual Income, $ -82,180 K
  • EBIT $ -92 M
  • EBITDA $ -89 M
  • 60-Month Beta 1.38
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book 0.40

Options Overview Details

View History
  • Implied Volatility 118.34% ( -0.56%)
  • Historical Volatility 79.21%
  • IV Percentile 43%
  • IV Rank 21.33%
  • IV High 499.67% on 08/05/24
  • IV Low 14.94% on 10/17/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 106
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 15,281
  • Open Int (30-Day) 15,493

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Sell
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.20
  • Number of Estimates 2
  • High Estimate -1.00
  • Low Estimate -1.40
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.52 +21.08%
on 04/07/25
Period Open: 8.30
10.10 -9.80%
on 04/11/25
+0.81 (+9.76%)
since 03/17/25
3-Month
7.08 +28.67%
on 03/12/25
Period Open: 11.16
13.40 -31.99%
on 01/24/25
-2.05 (-18.37%)
since 01/17/25
52-Week
7.08 +28.67%
on 03/12/25
Period Open: 18.34
20.60 -55.78%
on 05/07/24
-9.23 (-50.33%)
since 04/17/24

Most Recent Stories

More News
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

AMRN : 9.11 (-2.67%)
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors

AMRN : 9.11 (-2.67%)
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist

AMRN : 9.11 (-2.67%)
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American...

AMRN : 9.11 (-2.67%)
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript

AMRN earnings call for the period ending December 31, 2024.

AMRN : 9.11 (-2.67%)
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program

AMRN : 9.11 (-2.67%)
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action 

AMRN : 9.11 (-2.67%)
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

AMRN : 9.11 (-2.67%)
Amarin Receives National Reimbursement for VAZKEPA® in Austria

AMRN : 9.11 (-2.67%)
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

AMRN : 9.11 (-2.67%)

Business Summary

Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating...

See More

Key Turning Points

3rd Resistance Point 9.85
2nd Resistance Point 9.60
1st Resistance Point 9.35
Last Price 9.11
1st Support Level 8.85
2nd Support Level 8.60
3rd Support Level 8.35

See More

52-Week High 20.60
Fibonacci 61.8% 15.44
Fibonacci 50% 13.84
Fibonacci 38.2% 12.24
Last Price 9.11
52-Week Low 7.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro